JP4060596B2 - １，４−ジアゼパン−２，５−ジオン誘導体、およびｎｋ−１受容体アンタゴニストとしてのその使用 - Google Patents

１，４−ジアゼパン−２，５−ジオン誘導体、およびｎｋ−１受容体アンタゴニストとしてのその使用 Download PDF

Info

Publication number
JP4060596B2
JP4060596B2 JP2001586272A JP2001586272A JP4060596B2 JP 4060596 B2 JP4060596 B2 JP 4060596B2 JP 2001586272 A JP2001586272 A JP 2001586272A JP 2001586272 A JP2001586272 A JP 2001586272A JP 4060596 B2 JP4060596 B2 JP 4060596B2
Authority
JP
Japan
Prior art keywords
formula
dichlorobenzyl
compound
ylmethyl
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001586272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003534332A (ja
JP2003534332A5 (enExample
Inventor
ガレイ，グウィード
ゴーグレー，アニック
ゴデル，ティエリー
ヘック，ラインハルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2003534332A publication Critical patent/JP2003534332A/ja
Publication of JP2003534332A5 publication Critical patent/JP2003534332A5/ja
Application granted granted Critical
Publication of JP4060596B2 publication Critical patent/JP4060596B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2001586272A 2000-05-25 2001-05-18 １，４−ジアゼパン−２，５−ジオン誘導体、およびｎｋ−１受容体アンタゴニストとしてのその使用 Expired - Fee Related JP4060596B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00111249 2000-05-25
EP00111249.9 2000-05-25
PCT/EP2001/005723 WO2001090083A1 (en) 2000-05-25 2001-05-18 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2003534332A JP2003534332A (ja) 2003-11-18
JP2003534332A5 JP2003534332A5 (enExample) 2007-09-06
JP4060596B2 true JP4060596B2 (ja) 2008-03-12

Family

ID=8168838

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001586272A Expired - Fee Related JP4060596B2 (ja) 2000-05-25 2001-05-18 １，４−ジアゼパン−２，５−ジオン誘導体、およびｎｋ−１受容体アンタゴニストとしてのその使用

Country Status (18)

Country Link
US (1) US6452001B2 (enExample)
EP (1) EP1296961B1 (enExample)
JP (1) JP4060596B2 (enExample)
KR (1) KR100526696B1 (enExample)
CN (1) CN1178923C (enExample)
AR (1) AR028607A1 (enExample)
AT (1) ATE353881T1 (enExample)
AU (2) AU2001281778B2 (enExample)
BR (1) BR0111062A (enExample)
CA (1) CA2409842C (enExample)
DE (1) DE60126614T2 (enExample)
DK (1) DK1296961T3 (enExample)
ES (1) ES2280392T3 (enExample)
MX (1) MXPA02011464A (enExample)
PE (1) PE20011266A1 (enExample)
PT (1) PT1296961E (enExample)
WO (1) WO2001090083A1 (enExample)
ZA (1) ZA200208940B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
DE602006016168D1 (de) * 2005-12-29 2010-09-23 Immupharma France Sa 1,3,5-triazepin-dionen zur Behandlung von Malaria
US7777030B2 (en) 2005-12-29 2010-08-17 Centre National de la Recherge Scientifique (CNRS) Compositions and methods for the treatment and prevention of disease
AU2006331357B2 (en) * 2005-12-29 2012-05-17 Immupharma France Sa Compositions and methods for synthesizing novel heterocyclic therapeutics
JP2009522236A (ja) * 2005-12-29 2009-06-11 イミュファルマ・フランス・エスアー マラリアまたはエイズの処置のためのアザ複素環化合物
AU2006331355B2 (en) * 2005-12-29 2011-09-29 Immupharma France Sa Compositions and methods for the inhibition of phospholipase A2
WO2007139992A2 (en) * 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
KR101044833B1 (ko) * 2010-02-10 2011-06-28 (주)혜성나노텍 무차광 온실 보온커텐 종형 개폐장치
CN103951624B (zh) * 2010-08-26 2019-04-16 兴和株式会社 1,4-二氮杂环庚烷衍生物或其盐的制造方法
CA2839385C (en) 2011-06-24 2018-10-30 Construction Research & Technology Gmbh Cementitious composition and admixture
CN108358893A (zh) * 2018-02-10 2018-08-03 安徽唯诗杨信息科技有限公司 一种一锅法合成四氢化苯并-[1,4]-二氮杂环庚烷衍生物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022765A (en) 1975-01-06 1977-05-10 E. R. Squibb & Sons, Inc. Triazolo[4,3-d][1,4]benzodiazepine-6-ones
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5719156A (en) 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
DE60126614D1 (de) 2007-03-29
ZA200208940B (en) 2004-02-04
AR028607A1 (es) 2003-05-14
BR0111062A (pt) 2003-06-10
KR20030003759A (ko) 2003-01-10
JP2003534332A (ja) 2003-11-18
DE60126614T2 (de) 2007-11-22
CA2409842A1 (en) 2001-11-29
DK1296961T3 (da) 2007-06-04
ES2280392T3 (es) 2007-09-16
EP1296961A1 (en) 2003-04-02
MXPA02011464A (es) 2003-04-25
US6452001B2 (en) 2002-09-17
ATE353881T1 (de) 2007-03-15
KR100526696B1 (ko) 2005-11-08
AU8177801A (en) 2001-12-03
PT1296961E (pt) 2007-05-31
CN1430611A (zh) 2003-07-16
EP1296961B1 (en) 2007-02-14
CA2409842C (en) 2008-07-29
WO2001090083A1 (en) 2001-11-29
CN1178923C (zh) 2004-12-08
US20020010174A1 (en) 2002-01-24
PE20011266A1 (es) 2001-12-14
AU2001281778B2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
US8912220B2 (en) Compounds and methods of use thereof
CN103596567B (zh) 吡唑衍生物
JPH08504435A (ja) タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
RU2637938C2 (ru) Производные триазолкарбоксамида
JPH10506399A (ja) １−アシル−４−マリファチルアミノピペリジン化合物
PT763031E (pt) Derivados da piperazina como antagonistas 5ht1a
JP2002504929A (ja) アロイルピペラジン誘導体、その製造法およびタキキニン拮抗剤としてのその利用
US6452001B2 (en) Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
CN102686572A (zh) 用于治疗cns病的噁唑啉衍生物
JP2001151754A (ja) ２−（３，５−ビス−トリフルオロメチル−フェニル）−Ｎ−メチル−Ｎ−（６−モルホリン−４−イル−４−ｏ−トリル−ピリジン−３−イル）−イソブチルアミド
BR112015004511B1 (pt) Derivados de pirazol carboxamida como moduladores de taar para uso no tratamento de diversas desordens, tais como depressão, diabetes e doença de parkinson
AU2001281778A1 (en) 1,4-diazepan-2,5-dione derivatives and their use as NK-1 receptor antagonists
JPH11500436A (ja) １−アリール−２−アシルアミノ−エタン化合物およびニューロキニン特にニューロキニン１アンタゴニストとしてのそれらの用途
US20080306055A1 (en) Heterocyclic Mchr1 Antagonists And Their Use In Therapy
JPH08119936A (ja) 複素環式誘導体
WO2007109615A2 (en) β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
KR101189031B1 (ko) Ｎｋ3 길항물질로서의 스피로피페리딘 유도체
SK13462001A3 (sk) Morfolínové deriváty, spôsob ich prípravy a farmaceutické prostriedky obsahujúce tieto zlúčeniny
CN103459379B (zh) 甘氨酸转运体抑制物质
CN101801927A (zh) 作为nk3受体拮抗剂的哌啶衍生物
AU2008263982B2 (en) Piperazine and [1,4] diazepan derivatives as NK antagonists
CN101230008A (zh) 取代的杂环化合物、其制备方法和含有这些化合物的药物组合物
JP2004522705A (ja) アミジノ−尿素セロトニン受容体リガンドおよび組成物、その医薬的使用およびその合成方法
JPWO2001032173A1 (ja) カイニン酸神経細胞毒性阻害剤

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070420

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070720

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071220

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101228

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees